Clinical Trial Search

Primary: Percentage of Participants With Delirium as Assessed by Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) Criteria — 16.8; 26.5 Percentage of…

Primary: Number of Participants With Dose Limiting Toxicities (DLTs), Treatment A — 0; 0; 0 Participants

Primary: Percentage of Participants Achieving Seroconversion One Week After Receiving Second Vaccine (EAS) — 52.9; 75.0; 90.0 percentage of participants

Primary: Subjective Rewarding Value of Cigarillo Flavoring — 4.03; 3.63; 3.30 score on a scale

Primary: Mean Total Visualization Score of Qualitative Endocardial Border Delineation (EBD) of the 12 Segments of the Left Ventricle (LV) Wall in Standard Apical 4-chamber (A4C)…

Primary: Rate of Local Solicited Adverse Events After Each Study Vaccination — 13; 17; 11; 23 Participants

Primary: Proportion of Participants That Experience at Least One Grade 3 or Higher Adverse Event at or Before Week 48. — 0.333; 0.000; 0.571; 0.000 Proportion of participants…

Primary: Sensitivity and Specificity of Qualitative Assessment of PET/CT Imaging With 89Zr-TLX250 to Noninvasively Detect ccRCC in Patients With Indeterminate Renal Masses, Using…

Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 23; 2 Participants

Primary: Mini Mental State Examination (MMSE) Score at the Second Hour After Surgery — 27.40; 26.45 scores on a scale

Primary: Ropivacaine Concentrations — 0; 0; 1232.25; 850.25 ng/mL

Primary: Tau Accumulation Measured by PET Imaging — 12 Participants

Primary: Death From All Causes — 10; 5 Participants

Primary: Parts A and B: Percentage of Flare-ups With No New Heterotopic Ossification (HO) at Week 12 — 64.3; 72.5 percentage of flare-ups

Primary: Number of Participants With Adverse Events — 3; 2; 3; 7 Participants